Silence Therapeutics Plc American Depository Share (SLN)
Stock · NASDAQ · Health Care
$8.68as of 10/16/2026
Price chart
Active signals
SLN Signal Track Record
How signals performed across all stocks →What SLN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +6.4% | 62% | August 12, 2026 |
| Bollinger Band Breakout | 26 | -4.3% | 46% | August 10, 2026 |
| Bollinger Band Breakdown | 23 | +2.2% | 57% | May 15, 2026 |
| 200-Day Moving Average TouchActive now | 11 | +25.8% | 73% | June 9, 2026 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SLN
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 88
Fundamentals
- 1-day range
- $8.66$9.22
- Market cap
- $548.50M
- P/E (trailing)
- —
- P/E (forward)
- -22.84
- EPS (trailing)
- $-0.48
- Dividend yield
- —
- Beta
- 2.88
- Avg. volume
- 1.20M
How Silence Therapeutics Plc American Depository Share Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Silence Therapeutics Plc American Depository Share Competitors
Chosen by industry and closest market cap.
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
- STTKShattuck Labs Inc. Common Stock$5.42▼ 1.99%Market cap $549.03MP/E —$1.7$8.33
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
- SGMTSagimet Biosciences Inc. Series A Common Stock$8.02▼ 1.84%Market cap $539.71MP/E —$4.5$11.45
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
| STTK Shattuck Labs Inc. Common Stock | $549.03M | — | $5.42 | ▼ 1.99% | $1.7$8.33 |
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $539.71M | — | $8.02 | ▼ 1.84% | $4.5$11.45 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Griffiths Richard Ian · August 10, 2026 · Sale50.0K
- Griffiths Richard Ian · August 10, 2026 · Sale2.79M
- Griffiths Richard Ian · August 10, 2026 · Sale100.0K
- Griffiths Richard Ian · August 10, 2026 · Sale60.0K
- Griffiths Richard Ian · August 10, 2026 · Sale120.0K
- Griffiths Richard Ian · August 10, 2026 · Sale605.2K
- Griffiths Richard Ian · August 10, 2026 · Sale470.8K
- Griffiths Richard Ian · August 10, 2026 · Sale382.0K
- Griffiths Richard Ian · August 10, 2026 · Sale800.0K
- Griffiths Richard Ian · August 10, 2026 · Sale3.5K
- Griffiths Richard Ian · July 6, 2026 · Sale865.1K
- Griffiths Richard Ian · July 2, 2026 · Sale50.1K
- Griffiths Richard Ian · July 1, 2026 · Sale50.0K
- Griffiths Richard Ian · July 1, 2026 · Sale79.2K
- Griffiths Richard Ian · June 30, 2026 · Sale169.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 19.95M
- Total value held
- $100.71M
- Institutional holders
- 55
- Unknown3.03M
- Unknown2.91M
- Unknown2.16M
- Unknown2.15M
- Unknown1.25M
- Unknown1.07M
- Unknown1.02M
- Unknown952.4K
- Unknown865.8K
- Unknown630.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Silence Therapeutics (SLN) receives analyst rating upgrade
An analyst has raised the rating on Silence Therapeutics' American Depository Shares, moving it to a more positive stance. The upgrade reflects confidence in the company's recent developments and may affect market perception. The stock is currently in a low RSI zone, suggesting limited recent trading activity.
Silence Therapeutics (SLN) receives analyst rating upgrade. An analyst has raised the rating on Silence Therapeutics' American Depository Shares, moving it to a more positive stance. The upgrade reflects confidence in the company's recent developments and may affect market perception. The stock is currently in a low RSI zone, suggesting limited recent trading activity.